Thrombospondin-1 expression in urothelial carcinoma: Prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Ioachim, E ^a   Michael, M C ^a   Salmas, M ^b   Damala, K ^a   Tsanou, E ^a   Michael, M M ^c   Malamou Mitsi, V ^a   Stavropoulos, N E ^d  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c RED CROSS HOSPITAL   (Greece)

^d G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; PARAFFIN; PROTEIN P53; TENASCIN; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; TISSUE PREPARATION; TUMOR DIFFERENTIATION; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CARCINOMA; CELL COUNT; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBRONECTINS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; TENASCIN; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33747146383     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-140     Document Type: Article

References (56)

1. Tuszynski GO, Rothman V, Murphy A, Siegler K, Smith L, Smith S, Karczewski J, Knudsen KA: Thrombospondin promotes cell-substratum adhesion. Science 1987, 234:1570-73.
2. Iruela-Arispe ML, Bornstein P, Sage H: Thrombospondin exerts an anti-angiogenic effect on cord formation by endothelial cells in votro. Proc Nat Acad Sci USA 1991, 88:5026-5030.
3. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M: Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci 1999, 96:14888-93.
4. Walz DA: Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev 1992, 11:313-24.
5. DiPietro LA: Thrombospondin as a regulator of angiogenesis. EXS 1997, 79:295-314.
6. Taraboletti G, Roberts D, Liotta LA, Giavazzi R: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990, 111:765-72.
7. Taraboletti G, Roberts DD, Liotta LA: Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987, 105:2409-15.
8. Nickoloff BJ, Mitra RS, Riser BL, Dixit VM, Varani J: Modulation of keratinocyte motility. Correlation with production of extracellular matrix molecules in response to growth promoting and antiproliferative factors. Am J Pathol 1988, 132:543-51.
9. Lahav J: The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993, 1182:1-14.
10. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH: Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem 1993, 41:1467-77.
11. Liska DJ, Hawkins R, Wikstrom K, Bornstein P: Modulation of thrombospondin expression during differentiation of embryonal carcinoma cells. J Cell Physiol 1994, 158:495-505.
12. Corless CL, Mendoza A, Collins T, Lawler J: Colocalization of thrombospondin and syndecan during murine development. Dev Dyn 1992, 193:346-58.
13. Tikhonenko AT, Black DJ, Linial ML: Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumour suppressor gene. J Biol Chem 1996, 271:30741-30747.
14. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997, 89:219-27.
15. Iozzo RV: Tumour stroma as a regulator of neoplastic behavior. Lab Invest 1995, 73:157-160.
16. Campbell SC, Volpert OV, Ivanovich M, Bouck NP: Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998, 58:1298-304.
17. Goddard JC, Sutton CD, Jones JL, O'Byrne KJ, Kockelbergh RC: Reduced Thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur Urol 2002, 42:464-468.
18. Hermanek P, Hutter LH, Sobin G, Wagner C, Wittekind TNM, (Eds): Atlas: Urinary Bladder. 4th edition. Springer, New York; 1997:309-314.
19. Stavropoulos NE, Hastazeris K, Filiadis I, Mihailidis I, Ioachim E, Liamis Z, Kalomiris P: Intravesical instillations of interferon gamma in the profylaxis of high risk superficial bladder cancer: results of a controlled prospective study. Scand J Urol Nephrol 2002, 36:218-222.
20. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW: Angiogenesis in bladder cancer: relationship between microvessel density and tumour prognosis. J Natl Cancer Inst 1995, 87:1603-12.
21. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995, 154:69-71.
22. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler IJ: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998, 58:808-14.
23. Tanaka Y, Kawamata H, Fujimoto K, Oyasu R: Angiogonesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol 1997, 157:683-688.
24. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone: Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999, 155:1967-1976.
25. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Tamaoki N, Ueyama Y: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 1999, 79:354-359.
26. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994, 59:191-195.
27. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000, 6:41-8.
28. Good DJ, Polverini P, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumour suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Nat Acad Sci USA 1990, 87:6624-6628.
29. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497-511.
30. Nicosia RF, Tuszynski GP: Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994, 124:183-193.
31. Ben Ezra D, Griffin BW, Maftzir G, Aharonov O: Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci 1993, 34:3601-3608.
32. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 1996, 69:135-54.
33. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
34. Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-502.
35. Rockwell S, Knisely JP: Hypoxia and angiogenesis in experimental tumor models therapeutic implications. in: Regulation of angiogenesis. Edited by: Goldberg ID, Rosen EM. Basel: Birkhauser Verlag, 1997:335.
36. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC: The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 2001, 165:2075-2081.
37. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, Hayashi K, Mosher DF, Sugimachi K, Tsuneyoshi M, Kuwano M: Enhanced expression of thrombospondin-1 and hypovascularity in human holangiocarcinoma. Hepatology 1998, 28:1512-1517.
38. Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G: Thrombospondin I and II messenger RNA expression in lung carcinoma relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999, 5:155-161.
39. Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG: Thrombospondin-1 is down regulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000, 191:1789-1798.
40. Gasparini G, Toi M, Biganzoli E, Dittadi R, Fanelli M, Morabito A, Boracchi P, Gion M: Thrombospondin-1 and -2 in node negative breast cancer correlation with angiogenenic factors, p53, cathepsin D, hormon receptors and prognosis. Oncology 2001, 60:72-80.
41. Madri JA, Pratt BM, Tucker AM: Phenotypic modulation of endothelial cells by transforming growth factor-β depends upon the composition and organization of the extracellular matrix. J Cell Biol 1988, 106:1375-1384.
42. Sutton AB, Canfield AE, Schor SL, Grant ME, Schor AM: The response of endothelial cells to TGFβ-1 is dependent upon cell shape, proliferative state and the nature of the substratum. J Cell Sci 1991, 99:777-787.
43. Mignatti P, Tsuboi R, Robbins E, Rifkin DB: In vitro angiogenesis on the human amniotic membrane: requirements for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989, 108:671-682.
44. Pepper MS, Belin D, Montesano R, Orci L, Vassali JD: Tranforming growth factor beta-1 modulates basic fibroblast growth factor-indiced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol 1990, 111:743-755.
45. George EL, Baldwin HS, Hynes RO: Fibronectins are essential for hearth and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997, 90:3073-3081.
46. Bowersox JC, Sorgente N: Chemotaxis of aortic endothelial cell in response to fibronectin. Cancer Res 1982, 42:2547-2551.
47. Madri JA, Pratt BM, Tucker AM: Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition of the extracellular matrix. J Cell Biol 1988, 106:1375-1384.
48. Nicosia RF, Bonnano E, Smith M: Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 1993, 154:654-661.
49. Chiuqet-Ehrismann R, Kalla P, Pearson CA, Beck K, Chiquet M: Tenascin interferes with fibronectin action. Cell 1988, 53:383-390.
50. Canfield AE, Schor AM: Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cells Science 1995, 108:797-809.
51. McCarthy JB, Skubitz APN, Lida J, Mooradian DL, Wilke MS, Furcht LT: Tumor cell adhesive mechanisms and their relationship to metastasis. Semin Cancer Biol 1991, 2:155-67.
52. Gould VE, Koukoulis GK, Virtanen I: Extracellular matrix proteins and their receptor in the normal, hyperplastic and neoplastic breast. Cell Differ Dev 1990, 32:409-16.
53. Tiitta O, Wahlstrom T, Virtanen I, Gould VE: Tenascin in inflammatory conditions and neoplasm of the urinary bladder. Virchows Arch B Cell Pathol 1993, 63:2983-2987.
54. Booth C, Harnden P, Selby PJ, Southgate J: Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic bladder. J Pathol 2002, 198:359-368.
55. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. Br J Urol 2005, 95:655-659.
56. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvaniti DL, Agnantis NJ, Pavlidis N: Immunohistochemical expression of extracellulr matrix components tenascin, fibronectin, collagen type IV nd laminin in breast cancer their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38:2362-2370.